WEKO3
アイテム
Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma : results from a 52‐week, open‐label study
https://tokushima-u.repo.nii.ac.jp/records/2007962
https://tokushima-u.repo.nii.ac.jp/records/20079623c7f9b08-10d8-4f3f-91df-1d25f95b68d4
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
bjd_176_3_741.pdf (447 KB)
|
.png)
|
| Item type | 文献 / Documents(1) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2020-09-23 | |||||||||||||||||||||||||||||
| アクセス権 | ||||||||||||||||||||||||||||||
| アクセス権 | open access | |||||||||||||||||||||||||||||
| 資源タイプ | ||||||||||||||||||||||||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||||||||||||||||||||||||
| 資源タイプ | journal article | |||||||||||||||||||||||||||||
| 出版社版DOI | ||||||||||||||||||||||||||||||
| 識別子タイプ | DOI | |||||||||||||||||||||||||||||
| 関連識別子 | https://doi.org/10.1111/bjd.14702 | |||||||||||||||||||||||||||||
| 言語 | ja | |||||||||||||||||||||||||||||
| 関連名称 | 10.1111/bjd.14702 | |||||||||||||||||||||||||||||
| 出版タイプ | ||||||||||||||||||||||||||||||
| 出版タイプ | VoR | |||||||||||||||||||||||||||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||||||||||||||||||||||||||
| タイトル | ||||||||||||||||||||||||||||||
| タイトル | Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma : results from a 52‐week, open‐label study | |||||||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||||||||
| タイトル別表記 | ||||||||||||||||||||||||||||||
| その他のタイトル | Brodalumab in patients with GPP and PsE | |||||||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||||||||
| 著者 |
ヤマサキ
× ヤマサキ
× ナカガワ
× 久保, 宜明
WEKO
1539
× オオタキ
|
|||||||||||||||||||||||||||||
| 抄録 | ||||||||||||||||||||||||||||||
| 内容記述タイプ | Abstract | |||||||||||||||||||||||||||||
| 内容記述 | Background A T‐helper (Th) cell subset Th17 preferentially produces interleukin (IL)‐17 and plays a pivotal role in the pathogenesis of psoriasis. However, the pathological roles of IL‐17 cascades in generalized pustular psoriasis (GPP) and psoriatic erythroderma (PsE) have not been well established. Objectives To evaluate the efficacy and safety of brodalumab, a human immunoglobulin G2 monoclonal antibody against human IL ‐17‐receptor A (IL‐17RA), in Japanese patients with GPP and PsE. Methods This was an open‐label, multicentre, long‐term phase III study in Japanese patients with rare and severe types of psoriasis. Patients received brodalumab 140 mg at day 1 and weeks 1 and 2, and then every 2 weeks until week 52. The primary endpoint was the Clinical Global Impression of Improvement (CGI). Safety evaluations included treatment‐emergent adverse events (AEs) and changes in laboratory parameters. Results A total of 12 patients with GPP and 18 with PsE were enrolled. Ten patients with GPP and 16 with PsE completed the study. At week 52 (last observation carried forward), CGI remission or improvement was achieved in 11 patients with GPP and 18 with PsE. The most commonly reported AE was nasopharyngitis (33·3%). Five serious AE s occurred during the study. However, none was considered treatment‐related. Conclusions Brodalumab significantly improved the symptoms of patients with GPP and PsE throughout the 52 weeks, and demonstrated favourable safety profiles without any new safety signals. Inhibition of IL‐17RA‐mediated signalling by brodalumab is expected to be a promising new treatment option for patients with GPP and PsE. |
|||||||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||||||||
| 書誌情報 |
en : British Journal of Dermatology 巻 176, 号 3, p. 741-751, 発行日 2016-04-23 |
|||||||||||||||||||||||||||||
| 収録物ID | ||||||||||||||||||||||||||||||
| 収録物識別子タイプ | ISSN | |||||||||||||||||||||||||||||
| 収録物識別子 | 13652133 | |||||||||||||||||||||||||||||
| 出版者 | ||||||||||||||||||||||||||||||
| 出版者 | British Association of Dermatologists | |||||||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||||||||
| 出版者 | ||||||||||||||||||||||||||||||
| 出版者 | Wiley & Sons | |||||||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||||||||
| 権利情報 | ||||||||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||||||||
| 権利情報 | This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License(https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. | |||||||||||||||||||||||||||||
| EID | ||||||||||||||||||||||||||||||
| 識別子 | 342245 | |||||||||||||||||||||||||||||
| 識別子タイプ | URI | |||||||||||||||||||||||||||||
| 言語 | ||||||||||||||||||||||||||||||
| 言語 | eng | |||||||||||||||||||||||||||||
